Accordingly, the inhibition of angiogenesis has been one of the therapeutic options in cancer and there are a variety of approved anti-angiogenic drugs; Bevacizumab, a neutralizing monoclonal antibody directed against VEGF, and tyrosine kinase inhibitors (RTKi) such as sorafenib, sunitinib, cediranib, and axitinib are the most commonly used ones in this category [13,14]. Here, VEGFA is linked to cancer.